Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294293 · ClinicalTrials.gov registry record · Phase 1
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01294293 is a Phase 1 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 20 participants.
The verdict
NCT01294293, a Phase 1 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of TLR8 agonist VTX-2337 and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Biological therapies, such as TLR8 agonist VTX-2337, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving TLR8 agonist VTX-2337 together with pegylated liposomal doxorubicin hydrochloride or paclitaxel may kill more tumor cells.
Interventions
- DRUG Paclitaxel
- OTHER Diagnostic Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Pegylated Liposomal Doxorubicin Hydrochloride
- DRUG TLR8 Agonist VTX-2337
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01294293
The ClinicalTrials.gov registry entry for NCT01294293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Paclitaxel is the first listed.
NCT01294293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01294293 about?
NCT01294293 is a clinical study titled "TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer". This phase I trial is studying the side effects and best dose of TLR8 agonist VTX-2337 and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Biological therapies, such as TLR8 agonist VTX-2...
What is the current status of trial NCT01294293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-03.
What interventions are being tested in trial NCT01294293?
The interventions under investigation include: Paclitaxel (DRUG), Diagnostic Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Pegylated Liposomal Doxorubicin Hydrochloride (DRUG), TLR8 Agonist VTX-2337 (DRUG).
Who is sponsoring clinical trial NCT01294293?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.